Drug
Miptenalimab clinical trials
Also written BI 754111.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses miptenalimab is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)CompletedPhase 1Boehringer IngelheimNCT03964233Written as BI 754111
- This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.CompletedPhase 1Boehringer IngelheimNCT03156114Written as BI 754111
- This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091TerminatedPhase 1Boehringer IngelheimNCT03780725Written as BI 754111
- This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of CancerCompletedEarly Phase 1Boehringer IngelheimNCT03433898Written as BI 754111
Given in every arm · 1 — miptenalimab is usual care beside what is tested
Codes
What other systems call miptenalimab · ClinicalTrials.gg INT017416
- UNII (FDA) NVCTROPV3PMIPTENALIMABOne source FDA
- NCI Thesaurus C150403MiptenalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NVCTROPV3P | MIPTENALIMAB | One source FDA |
| NCI Thesaurus | C150403 | Miptenalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.